<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39326868</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>10</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1520-4804</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><Issue>19</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>10</Day></PubDate></JournalIssue><Title>Journal of medicinal chemistry</Title><ISOAbbreviation>J Med Chem</ISOAbbreviation></Journal><ArticleTitle>Toward the Design of Allosteric Effectors: Gaining Comprehensive Control of Drug Properties and Actions.</ArticleTitle><Pagination><StartPage>17191</StartPage><EndPage>17206</EndPage><MedlinePgn>17191-17206</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1021/acs.jmedchem.4c01043</ELocationID><Abstract><AbstractText>While the therapeutic potential of allosteric drugs is increasingly realized, the discovery of effectors is largely incidental. The rational design of allosteric effectors requires new state-of-the-art approaches to account for the distinct characteristics of allosteric ligands and their modes of action. We present a broadly applicable computational framework for obtaining allosteric site-effector pairs, providing targeted, highly specific, and tunable regulation to any functional site. We validated the framework using the main protease from SARS-CoV-2 and the K-Ras<sup>G12D</sup> oncoprotein. High-throughput per-residue quantification of the energetics of allosteric signaling and effector binding revealed known drugs capable of inducing the required modulation upon binding. Starting from fragments of known well-characterized drugs, allosteric effectors and binding sites were designed and optimized simultaneously to achieve targeted and specific signaling to distinct functional sites, such as, for example, the switch regions of K-Ras<sup>G12D</sup>. The generic framework proposed in this work will be instrumental in developing allosteric therapies aligned with a precision medicine approach.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tee</LastName><ForeName>Wei-Ven</ForeName><Initials>WV</Initials><AffiliationInfo><Affiliation>Bioinformatics Institute (BII), Agency for Science, Technology and Research (A*STAR), 30 Biopolis Street, #07-01, Matrix, Singapore 138671, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Sylvester J M</ForeName><Initials>SJM</Initials><AffiliationInfo><Affiliation>Bioinformatics Institute (BII), Agency for Science, Technology and Research (A*STAR), 30 Biopolis Street, #07-01, Matrix, Singapore 138671, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berezovsky</LastName><ForeName>Igor N</ForeName><Initials>IN</Initials><Identifier Source="ORCID">0000-0002-3315-8483</Identifier><AffiliationInfo><Affiliation>Bioinformatics Institute (BII), Agency for Science, Technology and Research (A*STAR), 30 Biopolis Street, #07-01, Matrix, Singapore 138671, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biological Sciences (DBS), National University of Singapore (NUS), 8 Medical Drive, Singapore 117579, Singapore.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Med Chem</MedlineTA><NlmUniqueID>9716531</NlmUniqueID><ISSNLinking>0022-2623</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008024">Ligands</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.5.2</RegistryNumber><NameOfSubstance UI="D016283">Proto-Oncogene Proteins p21(ras)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C117307">KRAS protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000494" MajorTopicYN="N">Allosteric Regulation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015195" MajorTopicYN="Y">Drug Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000495" MajorTopicYN="Y">Allosteric Site</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008024" MajorTopicYN="N">Ligands</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016283" MajorTopicYN="N">Proto-Oncogene Proteins p21(ras)</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001665" MajorTopicYN="N">Binding Sites</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors
declare no competing financial interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>10</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>26</Day><Hour>19</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39326868</ArticleId><ArticleId IdType="pmc">PMC11472305</ArticleId><ArticleId IdType="doi">10.1021/acs.jmedchem.4c01043</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Guarnera E.; Berezovsky I. N. On the perturbation nature of allostery: sites, mutations, and signal modulation. Curr. Opin. Struct. Biol. 2019, 56, 18–27. 10.1016/j.sbi.2018.10.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sbi.2018.10.008</ArticleId><ArticleId IdType="pubmed">30439587</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunasekaran K.; Ma B.; Nussinov R. Is allostery an intrinsic property of all dynamic proteins?. Proteins 2004, 57 (3), 433–443. 10.1002/prot.20232.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/prot.20232</ArticleId><ArticleId IdType="pubmed">15382234</ArticleId></ArticleIdList></Reference><Reference><Citation>Wodak S. J.; Paci E.; Dokholyan N. V.; Berezovsky I. N.; Horovitz A.; Li J.; Hilser V. J.; Bahar I.; Karanicolas J.; Stock G.; et al. Allostery in Its Many Disguises: From Theory to Applications. Struct. 2019, 27 (4), 566–578. 10.1016/j.str.2019.01.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.str.2019.01.003</ArticleId><ArticleId IdType="pmc">PMC6688844</ArticleId><ArticleId IdType="pubmed">30744993</ArticleId></ArticleIdList></Reference><Reference><Citation>Nussinov R.; Tsai C. J. Allostery in disease and in drug discovery. Cell 2013, 153 (2), 293–305. 10.1016/j.cell.2013.03.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2013.03.034</ArticleId><ArticleId IdType="pubmed">23582321</ArticleId></ArticleIdList></Reference><Reference><Citation>Tee W. V.; Berezovsky I. N. Allosteric drugs: New principles and design approaches. Curr. Opin. Struct. Biol. 2024, 84, 102758.10.1016/j.sbi.2023.102758.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sbi.2023.102758</ArticleId><ArticleId IdType="pubmed">38171188</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J. A.; Wells J. A. Searching for new allosteric sites in enzymes. Curr. Opin. Struct. Biol. 2004, 14 (6), 706–715. 10.1016/j.sbi.2004.10.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sbi.2004.10.009</ArticleId><ArticleId IdType="pubmed">15582395</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner J. R.; Lee C. T.; Durrant J. D.; Malmstrom R. D.; Feher V. A.; Amaro R. E. Emerging Computational Methods for the Rational Discovery of Allosteric Drugs. Chem. Rev. 2016, 116 (11), 6370–6390. 10.1021/acs.chemrev.5b00631.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.chemrev.5b00631</ArticleId><ArticleId IdType="pmc">PMC4901368</ArticleId><ArticleId IdType="pubmed">27074285</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan Z. W.; Tee W. V.; Berezovsky I. N. Learning About Allosteric Drugs and Ways to Design Them. J. Mol. Biol. 2022, 434 (17), 167692.10.1016/j.jmb.2022.167692.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2022.167692</ArticleId><ArticleId IdType="pubmed">35738428</ArticleId></ArticleIdList></Reference><Reference><Citation>Nussinov R.; Tsai C. J. The different ways through which specificity works in orthosteric and allosteric drugs. Curr. Pharm. Des. 2012, 18 (9), 1311–1316. 10.2174/138161212799436377.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/138161212799436377</ArticleId><ArticleId IdType="pmc">PMC7458136</ArticleId><ArticleId IdType="pubmed">22316155</ArticleId></ArticleIdList></Reference><Reference><Citation>Berezovsky I. N. Thermodynamics of allostery paves a way to allosteric drugs. Biochim. Biophys. Acta 2013, 1834 (5), 830–835. 10.1016/j.bbapap.2013.01.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbapap.2013.01.024</ArticleId><ArticleId IdType="pubmed">23376182</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan Y.; Mader M. M. Principles of Kinase Allosteric Inhibition and Pocket Validation. J. Med. Chem. 2022, 65 (7), 5288–5299. 10.1021/acs.jmedchem.2c00073.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.2c00073</ArticleId><ArticleId IdType="pubmed">35312319</ArticleId></ArticleIdList></Reference><Reference><Citation>Conn P. J.; Christopoulos A.; Lindsley C. W. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat. Rev. Drug Discov. 2009, 8 (1), 41–54. 10.1038/nrd2760.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd2760</ArticleId><ArticleId IdType="pmc">PMC2907734</ArticleId><ArticleId IdType="pubmed">19116626</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J.; Nussinov R. Energetic redistribution in allostery to execute protein function. Proc. Natl. Acad. Sci. U.S.A. 2017, 114 (29), 7480–7482. 10.1073/pnas.1709071114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1709071114</ArticleId><ArticleId IdType="pmc">PMC5530713</ArticleId><ArticleId IdType="pubmed">28696318</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J.; Nussinov R. Allosteric effects in the marginally stable von Hippel-Lindau tumor suppressor protein and allostery-based rescue mutant design. Proc. Natl. Acad. Sci. U.S.A. 2008, 105 (3), 901–906. 10.1073/pnas.0707401105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0707401105</ArticleId><ArticleId IdType="pmc">PMC2242715</ArticleId><ArticleId IdType="pubmed">18195360</ArticleId></ArticleIdList></Reference><Reference><Citation>Rettenmaier T. J.; Sadowsky J. D.; Thomsen N. D.; Chen S. C.; Doak A. K.; Arkin M. R.; Wells J. A. A small-molecule mimic of a peptide docking motif inhibits the protein kinase PDK1. Proc. Natl. Acad. Sci. U.S.A. 2014, 111 (52), 18590–18595. 10.1073/pnas.1415365112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1415365112</ArticleId><ArticleId IdType="pmc">PMC4284534</ArticleId><ArticleId IdType="pubmed">25518860</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulze J. O.; Saladino G.; Busschots K.; Neimanis S.; Süß E.; Odadzic D.; Zeuzem S.; Hindie V.; Herbrand A. K.; Lisa M. N.; et al. Bidirectional Allosteric Communication between the ATP-Binding Site and the Regulatory PIF Pocket in PDK1 Protein Kinase. Cell Chem. Biol. 2016, 23 (10), 1193–1205. 10.1016/j.chembiol.2016.06.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chembiol.2016.06.017</ArticleId><ArticleId IdType="pubmed">27693059</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghode A.; Gross L. Z. F.; Tee W. V.; Guarnera E.; Berezovsky I. N.; Biondi R. M.; Anand G. S. Synergistic Allostery in Multiligand-Protein Interactions. Biophys. J. 2020, 119 (9), 1833–1848. 10.1016/j.bpj.2020.09.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bpj.2020.09.019</ArticleId><ArticleId IdType="pmc">PMC7677135</ArticleId><ArticleId IdType="pubmed">33086047</ArticleId></ArticleIdList></Reference><Reference><Citation>Guarnera E.; Berezovsky I. N. Structure-Based Statistical Mechanical Model Accounts for the Causality and Energetics of Allosteric Communication. PLoS Comput. Biol. 2016, 12 (3), e100467810.1371/journal.pcbi.1004678.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pcbi.1004678</ArticleId><ArticleId IdType="pmc">PMC4777440</ArticleId><ArticleId IdType="pubmed">26939022</ArticleId></ArticleIdList></Reference><Reference><Citation>Guarnera E.; Berezovsky I. N. Toward Comprehensive Allosteric Control over Protein Activity. Struct. 2019, 27 (5), 866–878.e1. 10.1016/j.str.2019.01.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.str.2019.01.014</ArticleId><ArticleId IdType="pubmed">30827842</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostrem J. M.; Peters U.; Sos M. L.; Wells J. A.; Shokat K. M. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 2013, 503 (7477), 548–551. 10.1038/nature12796.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature12796</ArticleId><ArticleId IdType="pmc">PMC4274051</ArticleId><ArticleId IdType="pubmed">24256730</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim D.; Herdeis L.; Rudolph D.; Zhao Y.; Böttcher J.; Vides A.; Ayala-Santos C. I.; Pourfarjam Y.; Cuevas-Navarro A.; Xue J. Y.; et al. Pan-KRAS inhibitor disables oncogenic signalling and tumour growth. Nature 2023, 619 (7968), 160–166. 10.1038/s41586-023-06123-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-023-06123-3</ArticleId><ArticleId IdType="pmc">PMC10322706</ArticleId><ArticleId IdType="pubmed">37258666</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan Z. W.; Tee W. V.; Samsudin F.; Guarnera E.; Bond P. J.; Berezovsky I. N. Allosteric perspective on the mutability and druggability of the SARS-CoV-2 Spike protein. Struct. 2022, 30 (4), 590–607.e4. 10.1016/j.str.2021.12.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.str.2021.12.011</ArticleId><ArticleId IdType="pmc">PMC8772014</ArticleId><ArticleId IdType="pubmed">35063064</ArticleId></ArticleIdList></Reference><Reference><Citation>Tee W. V.; Tan Z. W.; Guarnera E.; Berezovsky I. N. Conservation and Diversity in Allosteric Fingerprints of Proteins for Evolutionary-inspired Engineering and Design. J. Mol. Biol. 2022, 434 (17), 167577.10.1016/j.jmb.2022.167577.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2022.167577</ArticleId><ArticleId IdType="pubmed">35395233</ArticleId></ArticleIdList></Reference><Reference><Citation>Tee W. V.; Tan Z. W.; Lee K.; Guarnera E.; Berezovsky I. N. Exploring the Allosteric Territory of Protein Function. J. Phys. Chem. B 2021, 125 (15), 3763–3780. 10.1021/acs.jpcb.1c00540.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jpcb.1c00540</ArticleId><ArticleId IdType="pubmed">33844527</ArticleId></ArticleIdList></Reference><Reference><Citation>Tee W. V.; Guarnera E.; Berezovsky I. N. On the Allosteric Effect of nsSNPs and the Emerging Importance of Allosteric Polymorphism. J. Mol. Biol. 2019, 431 (19), 3933–3942. 10.1016/j.jmb.2019.07.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2019.07.012</ArticleId><ArticleId IdType="pubmed">31306666</ArticleId></ArticleIdList></Reference><Reference><Citation>Tee W. V.; Guarnera E.; Berezovsky I. N. Disorder driven allosteric control of protein activity. Curr. Res. Struct. Biol. 2020, 2, 191–203. 10.1016/j.crstbi.2020.09.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.crstbi.2020.09.001</ArticleId><ArticleId IdType="pmc">PMC8244471</ArticleId><ArticleId IdType="pubmed">34235479</ArticleId></ArticleIdList></Reference><Reference><Citation>Tee W. V.; Guarnera E.; Berezovsky I. N. Reversing allosteric communication: From detecting allosteric sites to inducing and tuning targeted allosteric response. PLoS Comput. Biol. 2018, 14 (6), e100622810.1371/journal.pcbi.1006228.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pcbi.1006228</ArticleId><ArticleId IdType="pmc">PMC6023240</ArticleId><ArticleId IdType="pubmed">29912863</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan Z. W.; Guarnera E.; Tee W. V.; Berezovsky I. N. AlloSigMA 2: paving the way to designing allosteric effectors and to exploring allosteric effects of mutations. Nucleic Acids Res. 2020, 48 (W1), W116–w124. 10.1093/nar/gkaa338.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkaa338</ArticleId><ArticleId IdType="pmc">PMC7319554</ArticleId><ArticleId IdType="pubmed">32392302</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan Z. W.; Tee W. V.; Guarnera E.; Berezovsky I. N. AlloMAPS 2: allosteric fingerprints of the AlphaFold and Pfam-trRosetta predicted structures for engineering and design. Nucleic Acids Res. 2023, 51 (D1), D345–d351. 10.1093/nar/gkac828.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkac828</ArticleId><ArticleId IdType="pmc">PMC9825619</ArticleId><ArticleId IdType="pubmed">36169226</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Q.; Xiong Y.; Zhu G. H.; Zhang Y. N.; Zhang Y. W.; Huang P.; Ge G. B. The SARS-CoV-2 main protease (M(pro)): Structure, function, and emerging therapies for COVID-19. MedComm 2022, 3 (3), e15110.1002/mco2.151.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mco2.151</ArticleId><ArticleId IdType="pmc">PMC9283855</ArticleId><ArticleId IdType="pubmed">35845352</ArticleId></ArticleIdList></Reference><Reference><Citation>Nussinov R.; Jang H. Direct K-Ras Inhibitors to Treat Cancers: Progress, New Insights, and Approaches to Treat Resistance. Annu. Rev. Pharmacol. Toxicol. 2024, 64, 231–253. 10.1146/annurev-pharmtox-022823-113946.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-pharmtox-022823-113946</ArticleId><ArticleId IdType="pubmed">37524384</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L.; Guo Z.; Wang F.; Fu L. KRAS mutation: from undruggable to druggable in cancer. Signal Transduction Targeted Ther. 2021, 6 (1), 386.10.1038/s41392-021-00780-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-021-00780-4</ArticleId><ArticleId IdType="pmc">PMC8591115</ArticleId><ArticleId IdType="pubmed">34776511</ArticleId></ArticleIdList></Reference><Reference><Citation>Steuten K.; Kim H.; Widen J. C.; Babin B. M.; Onguka O.; Lovell S.; Bolgi O.; Cerikan B.; Neufeldt C. J.; Cortese M.; et al. Challenges for Targeting SARS-CoV-2 Proteases as a Therapeutic Strategy for COVID-19. ACS Infect. Dis. 2021, 7 (6), 1457–1468. 10.1021/acsinfecdis.0c00815.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsinfecdis.0c00815</ArticleId><ArticleId IdType="pmc">PMC7901237</ArticleId><ArticleId IdType="pubmed">33570381</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu S.; Jang H.; Muratcioglu S.; Gursoy A.; Keskin O.; Nussinov R.; Zhang J. Ras Conformational Ensembles, Allostery, and Signaling. Chem. Rev. 2016, 116 (11), 6607–6665. 10.1021/acs.chemrev.5b00542.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.chemrev.5b00542</ArticleId><ArticleId IdType="pubmed">26815308</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammond J.; Leister-Tebbe H.; Gardner A.; Abreu P.; Bao W.; Wisemandle W.; Baniecki M.; Hendrick V. M.; Damle B.; Simon-Campos A.; et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. N. Engl. J. Med. 2022, 386 (15), 1397–1408. 10.1056/NEJMoa2118542.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2118542</ArticleId><ArticleId IdType="pmc">PMC8908851</ArticleId><ArticleId IdType="pubmed">35172054</ArticleId></ArticleIdList></Reference><Reference><Citation>Skoulidis F.; Li B. T.; Dy G. K.; Price T. J.; Falchook G. S.; Wolf J.; Italiano A.; Schuler M.; Borghaei H.; Barlesi F.; et al. Sotorasib for Lung Cancers with KRAS p.G12C Mutation. N. Engl. J. Med. 2021, 384 (25), 2371–2381. 10.1056/NEJMoa2103695.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2103695</ArticleId><ArticleId IdType="pmc">PMC9116274</ArticleId><ArticleId IdType="pubmed">34096690</ArticleId></ArticleIdList></Reference><Reference><Citation>Akinosoglou K.; Schinas G.; Gogos C. Oral Antiviral Treatment for COVID-19: A Comprehensive Review on Nirmatrelvir/Ritonavir. Viruses 2022, 14 (11), 2540.10.3390/v14112540.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14112540</ArticleId><ArticleId IdType="pmc">PMC9696049</ArticleId><ArticleId IdType="pubmed">36423149</ArticleId></ArticleIdList></Reference><Reference><Citation>Guarnera E.; Berezovsky I. N. Allosteric sites: remote control in regulation of protein activity. Curr. Opin. Struct. Biol. 2016, 37, 1–8. 10.1016/j.sbi.2015.10.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sbi.2015.10.004</ArticleId><ArticleId IdType="pubmed">26562539</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q.; Chen Y.; Ni D.; Huang Z.; Wei J.; Feng L.; Su J. C.; Wei Y.; Ning S.; Yang X.; et al. Targeting a cryptic allosteric site of SIRT6 with small-molecule inhibitors that inhibit the migration of pancreatic cancer cells. Acta Pharm. Sin. B 2022, 12 (2), 876–889. 10.1016/j.apsb.2021.06.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.apsb.2021.06.015</ArticleId><ArticleId IdType="pmc">PMC8897208</ArticleId><ArticleId IdType="pubmed">35256952</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao S.; Alshahrani M.; Gupta G.; Tao P.; Verkhivker G. Markov State Models and Perturbation-Based Approaches Reveal Distinct Dynamic Signatures and Hidden Allosteric Pockets in the Emerging SARS-Cov-2 Spike Omicron Variant Complexes with the Host Receptor: The Interplay of Dynamics and Convergent Evolution Modulates Allostery and Functional Mechanisms. J. Chem. Inf. Model. 2023, 63 (16), 5272–5296. 10.1021/acs.jcim.3c00778.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jcim.3c00778</ArticleId><ArticleId IdType="pmc">PMC11162552</ArticleId><ArticleId IdType="pubmed">37549201</ArticleId></ArticleIdList></Reference><Reference><Citation>Eberhardt J.; Santos-Martins D.; Tillack A. F.; Forli S. AutoDock Vina 1.2.0: New Docking Methods, Expanded Force Field, and Python Bindings. J. Chem. Inf. Model. 2021, 61 (8), 3891–3898. 10.1021/acs.jcim.1c00203.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jcim.1c00203</ArticleId><ArticleId IdType="pmc">PMC10683950</ArticleId><ArticleId IdType="pubmed">34278794</ArticleId></ArticleIdList></Reference><Reference><Citation>Cimermancic P.; Weinkam P.; Rettenmaier T. J.; Bichmann L.; Keedy D. A.; Woldeyes R. A.; Schneidman-Duhovny D.; Demerdash O. N.; Mitchell J. C.; Wells J. A.; et al. CryptoSite: Expanding the Druggable Proteome by Characterization and Prediction of Cryptic Binding Sites. J. Mol. Biol. 2016, 428 (4), 709–719. 10.1016/j.jmb.2016.01.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2016.01.029</ArticleId><ArticleId IdType="pmc">PMC4794384</ArticleId><ArticleId IdType="pubmed">26854760</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura S. R.; Hu H. P.; Ruvinsky A. M.; Sherman W.; Favia A. D. Deciphering Cryptic Binding Sites on Proteins by Mixed-Solvent Molecular Dynamics. J. Chem. Inf. Model. 2017, 57 (6), 1388–1401. 10.1021/acs.jcim.6b00623.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jcim.6b00623</ArticleId><ArticleId IdType="pubmed">28537745</ArticleId></ArticleIdList></Reference><Reference><Citation>Oleinikovas V.; Saladino G.; Cossins B. P.; Gervasio F. L. Understanding Cryptic Pocket Formation in Protein Targets by Enhanced Sampling Simulations. J. Am. Chem. Soc. 2016, 138 (43), 14257–14263. 10.1021/jacs.6b05425.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jacs.6b05425</ArticleId><ArticleId IdType="pubmed">27726386</ArticleId></ArticleIdList></Reference><Reference><Citation>He J.; Liu X.; Zhu C.; Zha J.; Li Q.; Zhao M.; Wei J.; Li M.; Wu C.; Wang J.; et al. ASD2023: towards the integrating landscapes of allosteric knowledgebase. Nucleic Acids Res. 2024, 52 (D1), D376–d383. 10.1093/nar/gkad915.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkad915</ArticleId><ArticleId IdType="pmc">PMC10767950</ArticleId><ArticleId IdType="pubmed">37870448</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowman G. R.; Geissler P. L. Equilibrium fluctuations of a single folded protein reveal a multitude of potential cryptic allosteric sites. Proc. Natl. Acad. Sci. U.S.A. 2012, 109 (29), 11681–11686. 10.1073/pnas.1209309109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1209309109</ArticleId><ArticleId IdType="pmc">PMC3406870</ArticleId><ArticleId IdType="pubmed">22753506</ArticleId></ArticleIdList></Reference><Reference><Citation>Corsello S. M.; Bittker J. A.; Liu Z.; Gould J.; McCarren P.; Hirschman J. E.; Johnston S. E.; Vrcic A.; Wong B.; Khan M.; et al. The Drug Repurposing Hub: a next-generation drug library and information resource. Nat. Med. 2017, 23 (4), 405–408. 10.1038/nm.4306.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.4306</ArticleId><ArticleId IdType="pmc">PMC5568558</ArticleId><ArticleId IdType="pubmed">28388612</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q.; Zheng M.; Huang Z.; Liu X.; Zhou H.; Chen Y.; Shi T.; Zhang J. Toward understanding the molecular basis for chemical allosteric modulator design. J. Mol. Graph. Model. 2012, 38, 324–333. 10.1016/j.jmgm.2012.07.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmgm.2012.07.006</ArticleId><ArticleId IdType="pubmed">23085171</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunther S.; Reinke P. Y. A.; Fernandez-Garcia Y.; Lieske J.; Lane T. J.; Ginn H. M.; Koua F. H. M.; Ehrt C.; Ewert W.; Oberthuer D.; et al. X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease. Science 2021, 372 (6542), 642–646. 10.1126/science.abf7945.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abf7945</ArticleId><ArticleId IdType="pmc">PMC8224385</ArticleId><ArticleId IdType="pubmed">33811162</ArticleId></ArticleIdList></Reference><Reference><Citation>Stromich L.; Wu N.; Barahona M.; Yaliraki S. N. Allosteric Hotspots in the Main Protease of SARS-CoV-2. J. Mol. Biol. 2022, 434 (17), 167748.10.1016/j.jmb.2022.167748.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2022.167748</ArticleId><ArticleId IdType="pmc">PMC9288249</ArticleId><ArticleId IdType="pubmed">35843284</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuce M.; Cicek E.; Inan T.; Dag A. B.; Kurkcuoglu O.; Sungur F. A. Repurposing of FDA-approved drugs against active site and potential allosteric drug-binding sites of COVID-19 main protease. Proteins 2021, 89 (11), 1425–1441. 10.1002/prot.26164.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/prot.26164</ArticleId><ArticleId IdType="pmc">PMC8441840</ArticleId><ArticleId IdType="pubmed">34169568</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewell X. Q.; Judd D. B.; Watson S. P.; Hann M. M. RECAP--retrosynthetic combinatorial analysis procedure: a powerful new technique for identifying privileged molecular fragments with useful applications in combinatorial chemistry. J. Chem. Inf. Comput. Sci. 1998, 38 (3), 511–522. 10.1021/ci970429i.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ci970429i</ArticleId><ArticleId IdType="pubmed">9611787</ArticleId></ArticleIdList></Reference><Reference><Citation>Irwin J. J.; Tang K. G.; Young J.; Dandarchuluun C.; Wong B. R.; Khurelbaatar M.; Moroz Y. S.; Mayfield J.; Sayle R. A. ZINC20-A Free Ultralarge-Scale Chemical Database for Ligand Discovery. J. Chem. Inf. Model. 2020, 60 (12), 6065–6073. 10.1021/acs.jcim.0c00675.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jcim.0c00675</ArticleId><ArticleId IdType="pmc">PMC8284596</ArticleId><ArticleId IdType="pubmed">33118813</ArticleId></ArticleIdList></Reference><Reference><Citation>Bickerton G. R.; Paolini G. V.; Besnard J.; Muresan S.; Hopkins A. L. Quantifying the chemical beauty of drugs. Nat. Chem. 2012, 4 (2), 90–98. 10.1038/nchem.1243.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nchem.1243</ArticleId><ArticleId IdType="pmc">PMC3524573</ArticleId><ArticleId IdType="pubmed">22270643</ArticleId></ArticleIdList></Reference><Reference><Citation>Sauer W. H.; Schwarz M. K. Molecular shape diversity of combinatorial libraries: a prerequisite for broad bioactivity. J. Chem. Inf. Comput. Sci. 2003, 43 (3), 987–1003. 10.1021/ci025599w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ci025599w</ArticleId><ArticleId IdType="pubmed">12767158</ArticleId></ArticleIdList></Reference><Reference><Citation>Baell J. B.; Holloway G. A. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J. Med. Chem. 2010, 53 (7), 2719–2740. 10.1021/jm901137j.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm901137j</ArticleId><ArticleId IdType="pubmed">20131845</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenk R.; Schipani A.; James D.; Krasowski A.; Gilbert I. H.; Frearson J.; Wyatt P. G. Lessons learnt from assembling screening libraries for drug discovery for neglected diseases. ChemMedChem 2008, 3 (3), 435–444. 10.1002/cmdc.200700139.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cmdc.200700139</ArticleId><ArticleId IdType="pmc">PMC2628535</ArticleId><ArticleId IdType="pubmed">18064617</ArticleId></ArticleIdList></Reference><Reference><Citation>Bemis G. W.; Murcko M. A. The properties of known drugs. 1. Molecular frameworks. J. Med. Chem. 1996, 39 (15), 2887–2893. 10.1021/jm9602928.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm9602928</ArticleId><ArticleId IdType="pubmed">8709122</ArticleId></ArticleIdList></Reference><Reference><Citation>Bos J. L.; Rehmann H.; Wittinghofer A. GEFs and GAPs: critical elements in the control of small G proteins. Cell 2007, 129 (5), 865–877. 10.1016/j.cell.2007.05.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2007.05.018</ArticleId><ArticleId IdType="pubmed">17540168</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng H.; Zhang Y.; Bos P. H.; Chambers J. M.; Dupont M. M.; Stockwell B. R. K-Ras(G12D) Has a Potential Allosteric Small Molecule Binding Site. Biochemistry 2019, 58 (21), 2542–2554. 10.1021/acs.biochem.8b01300.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.biochem.8b01300</ArticleId><ArticleId IdType="pmc">PMC8158984</ArticleId><ArticleId IdType="pubmed">31042025</ArticleId></ArticleIdList></Reference><Reference><Citation>Spencer-Smith R.; Koide A.; Zhou Y.; Eguchi R. R.; Sha F.; Gajwani P.; Santana D.; Gupta A.; Jacobs M.; Herrero-Garcia E.; et al. Inhibition of RAS function through targeting an allosteric regulatory site. Nat. Chem. Biol. 2017, 13 (1), 62–68. 10.1038/nchembio.2231.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nchembio.2231</ArticleId><ArticleId IdType="pmc">PMC5193369</ArticleId><ArticleId IdType="pubmed">27820802</ArticleId></ArticleIdList></Reference><Reference><Citation>Weng C.; Faure A. J.; Escobedo A.; Lehner B. The energetic and allosteric landscape for KRAS inhibition. Nature 2024, 626 (7999), 643–652. 10.1038/s41586-023-06954-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-023-06954-0</ArticleId><ArticleId IdType="pmc">PMC10866706</ArticleId><ArticleId IdType="pubmed">38109937</ArticleId></ArticleIdList></Reference><Reference><Citation>Monod J.; Changeux J. P.; Jacob F. Allosteric proteins and cellular control systems. J. Mol. Biol. 1963, 6, 306–329. 10.1016/S0022-2836(63)80091-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-2836(63)80091-1</ArticleId><ArticleId IdType="pubmed">13936070</ArticleId></ArticleIdList></Reference><Reference><Citation>Wold E. A.; Chen J.; Cunningham K. A.; Zhou J. Allosteric Modulation of Class A GPCRs: Targets, Agents, and Emerging Concepts. J. Med. Chem. 2019, 62 (1), 88–127. 10.1021/acs.jmedchem.8b00875.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.8b00875</ArticleId><ArticleId IdType="pmc">PMC6556150</ArticleId><ArticleId IdType="pubmed">30106578</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu X.; Smaill J. B.; Ding K. New Promise and Opportunities for Allosteric Kinase Inhibitors. Angew. Chem., Int. Ed. Engl. 2020, 59 (33), 13764–13776. 10.1002/anie.201914525.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/anie.201914525</ArticleId><ArticleId IdType="pubmed">31889388</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostrem J. M.; Shokat K. M. Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design. Nat. Rev. Drug Discov. 2016, 15 (11), 771–785. 10.1038/nrd.2016.139.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd.2016.139</ArticleId><ArticleId IdType="pubmed">27469033</ArticleId></ArticleIdList></Reference><Reference><Citation>Goyal B.; Goyal D. Targeting the Dimerization of the Main Protease of Coronaviruses: A Potential Broad-Spectrum Therapeutic Strategy. ACS Comb. Sci. 2020, 22 (6), 297–305. 10.1021/acscombsci.0c00058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acscombsci.0c00058</ArticleId><ArticleId IdType="pubmed">32402186</ArticleId></ArticleIdList></Reference><Reference><Citation>O’Boyle N. M.; Banck M.; James C. A.; Morley C.; Vandermeersch T.; Hutchison G. R. Open Babel: An open chemical toolbox. J. Cheminf. 2011, 3, 33.10.1186/1758-2946-3-33.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1758-2946-3-33</ArticleId><ArticleId IdType="pmc">PMC3198950</ArticleId><ArticleId IdType="pubmed">21982300</ArticleId></ArticleIdList></Reference><Reference><Citation>Forli S.; Huey R.; Pique M. E.; Sanner M. F.; Goodsell D. S.; Olson A. J. Computational protein-ligand docking and virtual drug screening with the AutoDock suite. Nat. Protoc. 2016, 11 (5), 905–919. 10.1038/nprot.2016.051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2016.051</ArticleId><ArticleId IdType="pmc">PMC4868550</ArticleId><ArticleId IdType="pubmed">27077332</ArticleId></ArticleIdList></Reference><Reference><Citation>RDKit: Open-source cheminformatic, Version 2022.03.2. https://www.rdkit.org (accessed
April 25, 2022).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>